Top Tweets for #Cellcounting
Having issues getting reliable #CellCounting results? π Although it may seem a straightforward process, a few ποΈ key factors can impact accuracy. π In our latest blog article, we explain common challenges & how to resolve them. π©βπ¬β
https://t.co/LOZuQQ2bGT
#CellCount #Lab
We're delighted that the π SpectraSlide has been featured in a β¨ New Technology Spotlight article by @Biocompare! π
π "SpectraSlide AP-1 Simplifies Sample Preparation for Accurate Cell Counting"
https://t.co/P7hHZCWa34
#CellCount #CellCounting #Lab #LabTech
ChemoMetec A/S | $CHEMM π©π°π¬π§ͺπ©βπ¬π§¬
On October 14, 2025, UCL, ACBE, UK announced that it had expanded its analytical capabilities with the installation of the ChemoMetec XM40, an automated cell density and viability analyzer.
#cellcounting #lifescience #healthcare #biotech
ChemoMetec A/S | $CHEMM π©π°π¬π§ͺπ©βπ¬π§¬
$CHEMM combines consumables recurring revenue, sticky workflows, and emerging software optionality. If management executes, the model can evolve into a platform with expanding margins, strong cash flow, & long-term defensibility
#cellcounting
ChemoMetec A/S | $CHEMM π©π°π¬π§ͺπ©βπ¬π§¬
$CHEMM combines consumables recurring revenue, sticky workflows, and emerging software optionality. If management executes, the model can evolve into a platform with expanding margins, strong cash flow, & long-term defensibility
#cellcounting
Market Update - share buyback
ChemoMetec A/S | $CHEMM
ChemoMetec A/S announces a share repurchase program approved by shareholders in the Annual General Meeting held today - October 09, 2025. Per the approval, the company is authorized to repurchase up to 10% of its own shares.
ChemoMetec A/S | $CHEMM π©π°π¬π§ͺπ©βπ¬π§¬
Quick summary notes β¬οΈ
#lifescience #cellcounting #healthcare #biotech
$CHEMM π©π°π¬π§ͺπ©βπ¬π§¬
From specialized hardware to a solutions provider, ChemoMetec is strategically evolving its high-margin "razor-and-blade" model to higher-margin software & automation solutions to capture new recurring revenue streams with its XcytoMatic platform
#cellcounting
In life the little things matter. In investing, small caps can too. A small-cap with big numbers.
ChemoMetec A/S | $CHEMM (DKK 10.95B | US$ 1.72B Mkt Cap) π©π°π¬π§ͺπ©βπ¬π§¬
FY25 EBITDA Margin = 52.1%
FY25 EBITDA Growth = 39%
FY25 EV/EBITDA = 40x
#cellcounting #lifescience
ChemoMetec A/S | $CHEMMπ¬π©π°
Your Cheat Sheet for Technology that Counts!
#lifescience #cellcounting #healthcare #biotechπ¬π§ͺπ©βπ¬π§¬
ChemoMetec A/S | $CHEMMπ¬π©π°
Your Cheat Sheet for Technology that Counts!
#lifescience #cellcounting #healthcare #biotechπ¬π§ͺπ©βπ¬π§¬
Cell Counting Market Overview
The #cellcounting market comprises the sale of instruments, consumables, and software used to count and analyze cells for applications ranging from basic biological research to advanced biopharmaceutical manufacturing.
#lifescience #biotech
Cell Counting Market Overview
The #cellcounting market comprises the sale of instruments, consumables, and software used to count and analyze cells for applications ranging from basic biological research to advanced biopharmaceutical manufacturing.
#lifescience #biotech
ChemoMetec A/S | $CHEMMπ¬π©π°
Industry: Healthcare
Sector: Life Sciences Tools & Services
Sub-sector: Cell Counting & Analysis
Forecasts: 10.21% CAGR to reach mkt size ~USD300B by 2030
Overview: $CHEMM is a #lifesciences company specializing in #cellcounting & analysis equipment
ChemoMetec A/S | $CHEMMπ¬π©π°
Industry: Healthcare
Sector: Life Sciences Tools & Services
Sub-sector: Cell Counting & Analysis
Forecasts: 10.21% CAGR to reach mkt size ~USD300B by 2030
Overview: $CHEMM is a #lifesciences company specializing in #cellcounting & analysis equipment
ChemoMetec A/S | $CHEMMπ¬π©π°
Boring until you see:
the 21.02% CAGR returns since IPO
10-Year CAGR
Revenue 19.25%
Op. Profit 31%
FCF 45%
FCFps 43%
10-Year Median Returns
ROIC 29.0%
10-Year Median Margins
Gross Profit 90%
Op. Profit 33%
FCF 27%
#lifescience #cellcounting
ChemoMetec A/S | $CHEMMπ¬π©π°
Boring until you see:
the 21.02% CAGR returns since IPO
10-Year CAGR
Revenue 19.25%
Op. Profit 31%
FCF 45%
FCFps 43%
10-Year Median Returns
ROIC 29.0%
10-Year Median Margins
Gross Profit 90%
Op. Profit 33%
FCF 27%
#lifescience #cellcounting
ChemoMetec A/S | $CHEMMπ¬π©π°
Boring until you see:
the 21.02% CAGR returns since IPO
10-Year CAGR
Revenue 19.25%
Op. Profit 31%
FCF 45%
FCFps 43%
10-Year Median Returns
ROIC 29.0%
10-Year Median Margins
Gross Profit 90%
Op. Profit 33%
FCF 27%
#lifescience #cellcounting
$CHEMMπ¬
ChemoMetec CEO Martin Helbo Behrens on Software as an earning stream, a potential new pillar and what potential they see in software - Analysts Q&A. emphasis mine:
Short Thesis
$CHEMM from milk #cellcounting to advanced cell analysis
ChemoMetec A/S is a π©π°#lifescience tools company, which makes cell counters and analysis equipment for pharma, #biotech, academic & research institutions and the food/agricultural sectorπ¬
#healthcare
1/8
$CHEMM long thesis
From milk #cellcounting to advanced cell analysis
ChemoMetec A/S is a π©π°#lifescience tools company, which makes cell counters and analysis equipment for pharma, #biotech, academic & research institutions and the food/agricultural sectorπ¬
#healthcare
1/3
ChemoMetec A/S - From milk cell counting to life science applications
$CHEMM 2024/25 Earnings Report π
REV: $495.57M (+21.7% YoY)
FCF: $177.58M (+64% YoY)
FCFps: $10.21(+65% YoY)
EPS: $10.71(+37% YoY)
Full Year 2026 Guidance ππ½
#lifesciences #cellcounting #biotech #healthcare
$CHEMM thesis in a nutshell: 4 charts
ChemoMetec A/S is a Danish #lifesciences medical device company specializing in the development, manufacture, and sale of automated cell counters and analysis equipment.
#cellcounting #healthcare #biotech
$CHEMM stock rose 252% since 2020, while FCF/share compounded 23% annually. The question now is whether future FCF growth can sustain the stock's momentum or if expectations have run ahead of fundamentals. If FCF keeps compounding, the stock could have room
#cellcounting #biotech
$CHEMM stock rose 252% since 2020, while FCF/share compounded 23% annually. The question now is whether future FCF growth can sustain the stock's momentum or if expectations have run ahead of fundamentals. If FCF keeps compounding, the stock could have room
#cellcounting #biotech
$CHEMM has grown FCF/share 155% since 2020 (23% CAGR) while diluted shares rose just 3%. With minimal dilution, nearly all growth accrues to shareholders. A classic case of disciplined capital structure enhancing per-share value creation.
#lifesciences #cellcounting #biotech
Last Seen Hashtags on Sotwe
boner
Seen from Turkey
NOlimit filter:videos
Seen from Indonesia
nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit
Seen from Germany
AIDevelopmentCost
Seen from United States
momson()******momson() filter:native_video
teenager #momson #nolimit #teenagegirls
Seen from Turkey
artist
Seen from Brazil
μ΄λ
Seen from Thailand
Gay
Seen from Chile
Most Popular Users
Elon Musk 
@elonmusk
240.4M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.2M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.6M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.8M followers
KATY PERRY
@katyperry
87.5M followers
Taylor Swift
@taylorswift13
81.3M followers
Lady Gaga
@ladygaga
72.8M followers
Kim Kardashian
@kimkardashian
69.7M followers
Virat Kohli
@imvkohli
69.6M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
63.8M followers
The Ellen Show
@theellenshow
62.5M followers
Neymar Jr
@neymarjr
62.3M followers
CNN
@cnn
61.9M followers
X
@x
60.8M followers
Selena Gomez
@selenagomez
60.5M followers